ArticleWorld journal of urology2025
Distribution and resistance patterns of male urethritis pathogens from a private South African laboratory.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the microbial aetiology and antimicrobial resistance patterns in male urethritis syndrome by analysing private laboratory urethral swab and urine specimens. The study also compared diagnostic performance between nucleic acid amplification testing and culture and evaluated the relevance of syndromic management. This is the first large-scale South African private sector analysis of male urethritis syndrome pathogen profiles and antimicrobial resistance using nucleic acid amplification testing and culture, providing critical evidence for diagnostic and management policy updates.
methodsA retrospective cross-sectional study was performed using laboratory data from 2012 to 2023, comprising over 61 000 samples. Organism prevalence and antimicrobial resistance rates were assessed. Diagnostic sensitivity and specificity of nucleic acid amplification testing versus culture for Neisseria gonorrhoeae were calculated in matched samples.
resultsNG and Chlamydia trachomatis were the most prevalent pathogens. Nucleic acid amplification testing demonstrated superior sensitivity, while culture yielded essential antimicrobial resistance data. NG showed elevated resistance patterns, but susceptibility to first-line antimicrobials remained high. Culture sensitivity and specificity relative to nucleic acid amplification testing were 56% and 98.6%, respectively. Ureaplasma urealyticum showed elevated resistance versus global averages. The first cases of extensively drug-resistant NG in South Africa were identified.
conclusionNucleic acid amplification testing improves male urethritis syndrome detection, while culture remains vital for antimicrobial resistance surveillance. Syndromic management remains effective but rising resistance and extensively drug-resistant NG emergence warrants urgent attention.
Indexed as
Identifiers
41379237What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.